Vaishali Pharma Intrinsic Value
Vaishali Pharma (VAISHALI) median intrinsic value is ₹14.23 from 9 valuation models (range ₹2–₹19), vs current price ₹7.71 — +84.6% upside (Trading Below Calculated Value), margin of safety 45.8%. For current market price and key ratios, visit VAISHALI stock overview.
VAISHALI Valuation Methods Summary — DCF, Graham Number & P/E
Vaishali Pharma intrinsic value across 9 models vs current price ₹7.71 — upside/downside and value range per method. Browse VAISHALI cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹7.92 | ₹6.34 - ₹9.50 | +2.7% | EPS: ₹0.36, Sector P/E: 22x |
| Book Value Method | asset | ₹19.27 | ₹17.34 - ₹21.20 | +149.9% | Book Value/Share: ₹25.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹15.42 | ₹13.88 - ₹16.96 | +100.0% | Revenue/Share: ₹52.31, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹15.42 | ₹13.88 - ₹16.96 | +100.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3.57 | ₹2.86 - ₹4.28 | -53.7% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2.31 | ₹2.08 - ₹2.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹5.56 | ₹5.00 - ₹6.12 | -27.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹15.38 | ₹13.84 - ₹16.92 | +99.5% | ROE: 6.2%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹14.23 | ₹12.81 - ₹15.65 | +84.6% | EPS: ₹0.36, BVPS: ₹25.00 |
VAISHALI Intrinsic Value vs Market Price — All Valuation Models
Vaishali Pharma fair value range ₹2–₹19 vs current market price ₹7.71 across 9 valuation models. Compare with VAISHALI fundamental valuation to assess whether the stock is under or overvalued.
VAISHALI Intrinsic Value Analysis — Undervalued or Overvalued?
Vaishali Pharma median intrinsic value ₹14.23, current price ₹7.71 — Trading Below Calculated Value by 84.6%, margin of safety 45.8%.
What is the intrinsic value of VAISHALI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vaishali Pharma (VAISHALI) is ₹14.23 (median value). With the current market price of ₹7.71, this represents a +84.6% variance from our estimated fair value.
The valuation range spans from ₹2.31 to ₹19.27, indicating ₹2.31 - ₹19.27.
Is VAISHALI undervalued or overvalued?
Based on our multi-method analysis, Vaishali Pharma (VAISHALI) appears to be trading below calculated value by approximately 84.6%.
VAISHALI Financial Health — Key Ratios vs Industry Benchmarks
Vaishali Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 21.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.69 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 6.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.24x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VAISHALI Cash Flow Quality — Operating & Free Cash Flow
Vaishali Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-18 Cr | ₹-18 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |